Targan SR - Search Results

1

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: targan sr. Inflamm Bowel Dis. 2001 Aug;7(3):181-9. doi: 10.1097/00054725-200108000-00001. Inflamm Bowel Dis. 2001. PMID: 11515842 Clinical Trial.

2

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. Vasiliauskas EA, et al. Among authors: targan sr. Gastroenterology. 1999 Dec;117(6):1278-87. doi: 10.1016/s0016-5085(99)70277-5. Gastroenterology. 1999. PMID: 10579968 Clinical Trial.

3

Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease.

Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Hassard PV, et al. Among authors: targan sr. Inflamm Bowel Dis. 2000 Feb;6(1):16-20. doi: 10.1097/00054725-200002000-00003. Inflamm Bowel Dis. 2000. PMID: 10701145

4

Long-term outcomes of thalidomide in refractory Crohn's disease.

Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Gerich ME, et al. Among authors: targan sr. Aliment Pharmacol Ther. 2015 Mar;41(5):429-37. doi: 10.1111/apt.13057. Epub 2014 Dec 15. Aliment Pharmacol Ther. 2015. PMID: 25511905 Free article.

5

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Vasiliauskas EA, et al. Among authors: targan sr. Gastroenterology. 1996 Jun;110(6):1810-9. doi: 10.1053/gast.1996.v110.pm8964407. Gastroenterology. 1996. PMID: 8964407

6

Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications.

Facklis K, Plevy SE, Vasiliauskas EA, Kam L, Taylor K, Targan SR, Fleshner PR. Facklis K, et al. Among authors: targan sr. Dis Colon Rectum. 1999 May;42(5):601-5; discussion 605-6. doi: 10.1007/BF02234133. Dis Colon Rectum. 1999. PMID: 10344681

7

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Dubinsky MC, et al. Among authors: targan sr. Gastroenterology. 2000 Apr;118(4):705-13. doi: 10.1016/s0016-5085(00)70140-5. Gastroenterology. 2000. PMID: 10734022 Clinical Trial.

8

Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.

Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Rowe FA, et al. Among authors: targan sr. Am J Gastroenterol. 2000 Aug;95(8):2000-8. doi: 10.1111/j.1572-0241.2000.02186.x. Am J Gastroenterol. 2000. PMID: 10950049

9

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Vasiliauskas EA, et al. Among authors: targan sr. Gut. 2000 Oct;47(4):487-96. doi: 10.1136/gut.47.4.487. Gut. 2000. PMID: 10986208 Free PMC article.

10

TNF-alpha antagonists for the treatment of Crohn's disease.

Kam LY, Targan SR. Kam LY, et al. Among authors: targan sr. Expert Opin Pharmacother. 2000 May;1(4):615-22. doi: 10.1517/14656566.1.4.615. Expert Opin Pharmacother. 2000. PMID: 11249506 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

337 results

Search Page